Figure 2
From: Current pharmacologic options for patients with Alzheimer's disease
Cognitive function in AD patients receiving donepezil 5 or 10 mg/day or placebo [22]. Values are mean (± standard error of the mean [SEM]) change from baseline. Reassessment 6 weeks after withdrawal of donepezil reveals that the benefits of drug treatment were lost upon withdrawal. (From Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology. 1998;50:136-45.)